Advances in Therapy

, Volume 31, Issue 8, pp 837–860

Advances in Clinical Cardiology

  • Andrew H. McNeice
  • Neil M. McAleavey
  • Ian B. A. Menown


Multiple, potentially practice-changing cardiology trials have been presented or published over the past year. In this paper, we summarize and place in clinical context, new data regarding management of acute coronary syndrome and ST-elevation myocardial infarction (copeptin assessment, otamixaban, cangrelor, prasugrel, sodium nitrite, inclacumab, ranolazine, preventive coronary intervention of non-culprit lesions, immediate thrombolytic therapy versus transfer for primary intervention), new coronary intervention data (thrombectomy, radial access, pressure wire fractional flow reserve, antiplatelet therapy duration and gene-guidance, permanent and biodegradable polymers, coronary bifurcation and strategies), and coronary artery bypass data (off pump vs. on pump). Latest trials in trans-aortic valve implantation, heart failure (eplerenone, aliskiren, spironolactone, sildenafil, dopamine, nesiritide, omecamtiv mecarbil, the algisyl left ventricular augmentation device, and echo-guided cardiac resynchronization), atrial fibrillation (edoxaban, dabigatran, and ablation), cardiac arrest (hypothermia, LUCAS™ mechanical chest compression), and cardiovascular prevention (vitamins, renal denervation for resistant hypertension, renal artery stenting, saxagliptin, alogliptin, and gastric banding) are also discussed.


Acute coronary syndrome Anticoagulation Antiplatelet Atrial fibrillation Cardiac resynchronisation Drug-eluting stent Lipids Renal denervation 

Supplementary material

12325_2014_141_MOESM1_ESM.pdf (190 kb)
Supplementary material 1 (PDF 189 kb)


  1. 1.
    Moeckel M, Searle J, Hamm C, et al. Biomarkers in Cardiology-8, (BIC-8). Instant early rule-out using cardiac troponin and copeptin in low-to medium-risk patients with suspected ACS: a prospective, randomised, multicentre study for early discharge. Presented at the European Society of Cardiology 2013 Congress, 3rd Sept 2013; Amsterdam, Netherlands.Google Scholar
  2. 2.
    Steg P, Mehta SR, Pollack CV Jr, et al. Anticoagulation with otamixaban and ischaemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA. 2013;310(11):1145–55.PubMedCrossRefGoogle Scholar
  3. 3.
    Steg G, Bhatt D, Hamm C. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382(9909):1981–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Wald D, Morris J, Wald N, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369:1115–23.PubMedCrossRefGoogle Scholar
  5. 5.
    Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999–1010.PubMedCrossRefGoogle Scholar
  6. 6.
    Armstrong P, Gershlick, Van de Werf F, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013;368:1379–87.Google Scholar
  7. 7.
    Siddiqi N. The nitrites in acute myocardial infarction (NIAMI) trial. In: Presented at the American Heart Association Scientific Sessions, 7th Nov 2013; Dallas, Texas, USA.Google Scholar
  8. 8.
    Tardif J, Tanguay J, Wright SS, et al. Effects of the P-Selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol. 2013;61(20):2048–55.PubMedCrossRefGoogle Scholar
  9. 9.
    Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013;61(20):2038–45.PubMedCrossRefGoogle Scholar
  10. 10.
    Chevalier B, Montalescot G, Belle L. Genotyping infarct patients to adjust and normalize thienopyridine treatment (GIANT). In: Presented at transcatheter cardiovascular therapeutics (TCT), 31st Oct 2013; San Francisco, United States of America.Google Scholar
  11. 11.
    Collet JP, Montalescot G. Double randomization of a monitoring adjusted antiplatelet treatment versus a common antiplatelet treatment for DES implantation, and interruption versus continuation of double antiplatelet therapy-GENE, (ARCTIC-GENE). In: Presented at the European Society of Cardiology 2013 Congress, 4th Sept 2013; Amsterdam, Netherlands.Google Scholar
  12. 12.
    Fröbert O, Lagerqvist B, Olivecrona G, et al. Thrombus aspiration during ST-segment elevation myocardial infarction (TASTE). N Engl J Med. 2013;369:1587–97.PubMedCrossRefGoogle Scholar
  13. 13.
    Hess CN, Rao SV, Kong DF, et al. Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). Am Heart J. 2013;166(3):421–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Curzen N. Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain (RIPCORD). In: Presented at EuroPCR, 23rd May, 2013; Paris, France.Google Scholar
  15. 15.
    Feres F. OPTIMIzed duration of clopidogrel therapy following treatment with the endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE). In: Presented at TCT, 31st Oct 2013; San Francisco, United States of America.Google Scholar
  16. 16.
    Tandjung K, Basalus MW, von Birgelen C, et al. DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers population. Am Heart J. 2012;163(4):557–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Ruangaard B. Randomized Clinical Comparison of Biomatrix Flex® and Resolute Integrity®(SORT-OUT VI). In: Presented at transcatheter cardiovascular therapeutics (TCT), 29th Oct 2013; San Francisco, United States of America.Google Scholar
  18. 18.
    Windecker S. BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With Single de Novo Coronary Artery Lesions-II (BIOFLOW II). In: Presented at EuroPCR, 21st May 2013; Paris, France.Google Scholar
  19. 19.
    Maeng M, Holm NR, Erglis A, et al. Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results. J Am Coll of Cardiol. 2013;62(1):30–4.CrossRefGoogle Scholar
  20. 20.
    Kumsars I, Niemelä M, Erglis A, et al. Nordic-baltic bifurcation study IV. In: Presented at TCT, 3th Oct 2014, San Francisco.Google Scholar
  21. 21.
    Leon M. A prospective, randomized trial of a dedicated sidebranch stent vs. a provisional stent strategy in true coronary bifurcation lesions (TRYTON). In: Presented at transcatheter cardiovascular therapeutics (TCT), 30th Oct 2013, San Francisco, United States of America.Google Scholar
  22. 22.
    Diegeler A, Börgermann J, Kappert U, et al. Off-pump versus on-pump coronary-artery bypass grafting in elderly patients. N Engl J Med. 2013;368(13):1189–98.PubMedCrossRefGoogle Scholar
  23. 23.
    Lamy A, Devereaux PJ, Prabhakaran D, et al. Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med. 2013;368(13):1179–88.PubMedCrossRefGoogle Scholar
  24. 24.
    Popma J. Safety and efficacy study of the medtronic CoreValve® system in the treatment of symptomatic severe aortic stenosis in high risk and very high risk subjects who need aortic valve replacement. In: Presented at transcatheter cardiovascular therapeutics (TCT), 29th Oct 2013; San Francisco, United States of America.Google Scholar
  25. 25.
    Meredith I. REPRISE II: A prospective registry study of transcatheter aortic valve replacement with a repositionable transcatheter heart valve in patients with severe aortic stenosis. In: Presented at transcatheter cardiovascular therapeutics (TCT), 31st Oct 2013; San Francisco, United States of America.Google Scholar
  26. 26.
    Van de Werf F, Brueckmann M, Connolly S, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.PubMedCrossRefGoogle Scholar
  27. 27.
    Montalescot G, Zannad F, Lopez de Sa E, et al. Early administration of eplerenone in patients with acute myocardial infarction without heart failure: results of the randomized, double-blind, placebo-controlled REMINDER Trial. American College of Cardiology 2013 Scientific Sessions March 2013.Google Scholar
  28. 28.
    Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125–35.PubMedCrossRefGoogle Scholar
  29. 29.
    Pfeffer MA. TOPCAT Investigators. Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). American Heart Association Scientific Sessions, Nov 2013.Google Scholar
  30. 30.
    Redfield MM, Borlaug BA, Lewis GD, et al. Heart Failure Clinical Research Network. PhosphdiesteRasE-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: rationale and design. Circ Heart Fail. 2012;5(5):653–9.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA. 2013;309(12):1268–77.PubMedCrossRefGoogle Scholar
  32. 32.
    Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE Acute Heart Failure Randomized Trial. JAMA. 2013;310(23):2533–43.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Teerlink JR, Felker GM, McMurray JJV, et al. ATOMIC-AHF: acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: results from ATOMIC-AHF. European Society of Cardiology (ESC) Congress, Sept 2013.Google Scholar
  34. 34.
    Mann D, Sabbah H, Hinson A, et al. A multicentre randomized study assessing the efficacy of left ventricular augmentation with Algisyl-LVR in the treatment of advanced heart failure with ischaemic and non-ischaemic cardiomyopathy: interim results of the AUGMENT-HF Study. American Heart Association Scientific Sessions, Nov 2013.Google Scholar
  35. 35.
    Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395–405.PubMedCrossRefGoogle Scholar
  36. 36.
    Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66–74.PubMedCrossRefGoogle Scholar
  37. 37.
    Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.PubMedCrossRefGoogle Scholar
  38. 38.
    Atienza F. Radiofrequency catheter ablation of drivers vs. circumferential pulmonary vein isolation in patients with atrial fibrillation. In: Presented at: American Heart Association Scientific Sessions, Nov 2013.Google Scholar
  39. 39.
    Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed-enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014;311:498–506.PubMedCrossRefGoogle Scholar
  40. 40.
    Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013;369(23):2197–206.PubMedCrossRefGoogle Scholar
  41. 41.
    Rubertsson S, Lindgren E, Smekal D, et al. Mechanical chest compressions and simultaneous defibrillation vs conventional cardiopulmonary resuscitation in out-of-hospital cardiac arrest: the LINC randomized trial. JAMA. 2014;311:53–61.PubMedCrossRefGoogle Scholar
  42. 42.
    Gitt AK, Juenger C, Smolka, et al. Impact of a budget-restrictive (Germany) versus an incentive-driven (UK) reimbursement system on LDL goal achievement in statin-treated patients for secondary prevention: results of DYSIS. European Society of Cardiology Congress, Sept 2013.Google Scholar
  43. 43.
    Gitt AK, Juenger C, Smolka W, Wood D. Impact of pay-for-performance (UK) versus budget restricted (Germany) reimbursement system on LDL-goal-achievement in statin-treated patients for secondary prevention: results of DYSIS. American Heart Association Scientific Sessions, Nov 2013.Google Scholar
  44. 44.
    Lamas G, Boineau R, Goertz C, et al. Oral high-dose multivitamins and minerals after myocardial infarction a randomized trial. Ann Intern Med. 2013;159(12):797–805.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Worthley SG, Tsioufis CP, Worthley MI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:2132–40.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Scheinert D. Renal sympathetic denervation using a novel percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension. Interim analysis: REDUCE-HTN post-market study. In: Presented at: transcatheter cardiovascular therapeutics October 2013.Google Scholar
  47. 47.
    Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.PubMedCrossRefGoogle Scholar
  48. 48.
    Böhm M. The global SYMPLICITY registry: safety and effectiveness of renal artery denervation in real world patients with uncontrolled hypertension. In: Presented at: American College of Cardiology/i2 Scientific Session; 30 March 2013; Washington, DC.Google Scholar
  49. 49.
    Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotid renal artery disease. N Engl J Med. 2014;370(1):13–22.PubMedCrossRefGoogle Scholar
  50. 50.
    Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.PubMedCrossRefGoogle Scholar
  51. 51.
    White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.PubMedCrossRefGoogle Scholar
  52. 52.
    Heffron S, Singh A, Zagzag J, et al. Gastric banding resolves metabolic syndrome in obese subjects over five years follow-up. J Am Coll Cardiol. 2013;61.Google Scholar

Copyright information

© Springer Healthcare 2014

Authors and Affiliations

  • Andrew H. McNeice
    • 1
  • Neil M. McAleavey
    • 1
  • Ian B. A. Menown
    • 1
  1. 1.Craigavon Cardiac CentreSouthern TrustNorthern IrelandUK

Personalised recommendations